Career Development Award
Letter of Intent Deadline: TBA
Application Deadline: TBA
Award Start Date: TBA
The National Hemophilia Foundation (NHF), a nonprofit organization founded in 1948, is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy, and research. NHF seeks research grant applications from established investigators, preferably at the assistant professor level or above, who have demonstrated a commitment to bleeding disorders research. We especially encourage innovative projects that promote the development of novel technologies and/or therapies to advance the field of bleeding disorders research.
Career Development Award (CDA) candidates must hold a MD, PhD, or equivalent degree, with no more than six years of postdoctoral years of experience in hematology, nor more than six years since completion of medical training. United States citizenship is not required, but applicants must be affiliated with or be faculty members of a U.S.-based organization such as - universities, colleges, hospitals or laboratories. Only non-commercial institutions and investigators associated with a non-commercial institution are eligible to apply for this award.
The NHF/Novo Nordisk CDA award recipient will be expected to spend at least 75% of their working time on the funded research project. The CDA recipient and his/her mentor are also expected to remain at their institution for the duration of the project. For the application, letters of support from appropriate institutional officials (department chair and financial grants officer) indicating the institution’s commitment to allow the candidate to focus his/her efforts on the stated research project will be required.
NHF will award up to $70,000 annually for a maximum of three years. The funding for this award has been made possible by a generous grant from Novo Nordisk, Inc.
Scope of Research
NHF is interested in funding innovative research studies in bleeding disorders to be carried out at the sub cellular, cellular, animal or human/patient levels.
While gene therapy has been an approach which has shown much promise in hemophilia, no one method has been demonstrated to be superior. Multiple experimental strategies may be undertaken to help find a “cure” for bleeding disorders. NHF is seeking research proposals on the nature, propagation, and use of hematopoietic, liver, or stem cells as an approach for gene transfer in hemophilia or for other novel approaches for treating bleeding disorders.
Studies to evaluate the genetic and immunologic bases for inhibitor development may lead to strategies to circumvent this potential complication of clotting factor replacement and/or gene transfer. This research could provide the opportunity to determine the prognostic indicators that place patients at risk of inhibitor development. Inhibitor research may also lead to the development of synthetic replacement factor and gene therapy products with decreased immunogenicity. This includes research on genotype/phenotype relationships and susceptibility to inhibitors.
Structural studies of clotting factor proteins are needed in order to design more efficacious, longer-lived clotting factor proteins. Development of both small, biologically active, orally delivered molecules and improved protein delivery systems represent strategies that could lead to advances in our understanding of bleeding disorders. Better functional assays for clotting factor proteins are also needed. Reproducible, low-volume measure of factor VIII and factor IX activity in different animal models would greatly facilitate validation of in vivo gene therapy studies as well as innovative alternative treatment strategies.
All CDA research proposals are subjected to a rigorous peer review process. Applications will be reviewed on scientific merit and scored in terms of project significance, scientific approach, innovation, investigator qualifications and institutional environment.
All interested candidates need to submit a ‘Letter of Intent’ (LOI) by email to Dr. Michelle Witkop, Head of Research, at email@example.com by no later than TBA at 11:59 pm EST. Letters that do not arrive by the deadline will not be accepted.
LOIs need to be submitted on institutional letterhead and will not be considered for review unless signed by the candidate. LOIs should be: addressed to “Members of NHF’s Research Review Committee,” be 1 to 1.5 pages in length, include a brief introduction of the candidate/researcher and ability to meet eligibility criteria, information about his/her mentor, and a brief description of the proposed research project. Letters must be accompanied by a CV (NIH-style biosketch preferred) for both the candidate and his/her mentor.
LOIs will be evaluated by members of NHF’s Research Review Committee based on the candidate’s eligibility and relevance of the proposed research to the field of bleeding disorders. The committee will then collectively decide which candidates will be invited to submit a full application. The selected candidates will have until TBA at 11:59 pm EST to submit their full CDA application to NHF. Applications that do not arrive by the deadline will not be accepted.
CDA applications are subjected to a rigorous peer review process. Proposals are to be reviewed on scientific merit and scored in the areas of project significance, scientific approach, innovation, investigator qualifications and research environment.
All other inquiries regarding this or any other of NHF's research grant programs can be addressed to Dr. Michelle Witkop, NHF Head of Research, via email (firstname.lastname@example.org) or by phone at (347) 541-2963.
|CDA Policies||291.37 KB|
|CDA Initial Budget Template||112.54 KB|
|CDA Continuation Application Budget Template||162.4 KB|
|CDA Signature Page Initial Application||96.84 KB|
|CDA Signature Page Continuation Application||117.79 KB|
|Assurances and Certifications for Research Involving Humans/Animals Form||102.46 KB|